AMH (Anti-Müllerian Hormone): Normal Levels by Age, Test & Fertility

Anti-Müllerian hormone (AMH) has become the single most requested fertility hormone test worldwide — a one-time blood draw that estimates how many eggs a woman has left. But AMH is also one of the most misread numbers in reproductive medicine: patients frequently confuse "low AMH" with "infertile," and "high AMH" with "highly fertile." Neither is accurate. This guide covers what AMH actually measures, normal AMH levels by age, what low and high AMH mean clinically, how the AMH blood test works, and the real relationship between AMH and IVF success.

What Is AMH (Anti-Müllerian Hormone)?

AMH (anti-Müllerian hormone), also called Müllerian-inhibiting substance, is a glycoprotein hormone produced by the granulosa cells that surround small, growing (preantral and small antral) follicles in the ovary. Because the number of these early-stage follicles is proportional to a woman's total remaining egg supply, serum AMH concentration is used clinically as a marker of ovarian reserve — an estimate of egg quantity, not egg quality.

AMH has two properties that make it clinically convenient compared with other fertility hormones: it shows minimal fluctuation across the menstrual cycle, so it can be drawn on any day, and it is largely independent of the hypothalamic-pituitary-ovarian feedback loop that drives cycle-dependent swings in FSH, LH, and estradiol. AMH rises from birth, peaks around the mid-to-late 20s, then declines progressively through the 30s and 40s until it becomes undetectable roughly 5 years before the final menstrual period — making the AMH trajectory a biological clock for the ovarian follicle pool. (Source: Broer et al., Hum Reprod Update 2014)

Normal AMH Levels by Age

AMH levels by age follow a well-documented, gradually declining curve. The table below reflects commonly used clinical reference ranges, consistent with large age-stratified cohort data. (Source: Seifer et al., Fertil Steril 2011 — a cohort of 17,120 women presenting to U.S. fertility centers)

Age Group	Median AMH	Typical Range	Ovarian Reserve Interpretation
20-24 years	~3.8 ng/mL	3.0-5.0 ng/mL	High / expected for age
25-29 years	~3.2 ng/mL	2.5-4.0 ng/mL	Normal-high
30-34 years	~2.4 ng/mL	1.8-3.0 ng/mL	Normal
35-39 years	~1.5 ng/mL	1.0-2.0 ng/mL	Declining, expected for age
40+ years	~0.6 ng/mL	0.3-1.0 ng/mL	Low, consistent with reduced reserve

The average yearly decline in median AMH is approximately 0.2 ng/mL/year through age 35, slowing to roughly 0.1 ng/mL/year thereafter. Individual variation is substantial: two women of the same age can have AMH values that differ several-fold and both still fall within an expected range, which is why AMH is interpreted as a population-level trend rather than a precise individual prediction of remaining reproductive years.

Low AMH Levels — Causes & Fertility Impact

Low AMH — generally defined as below 1.0-1.1 ng/mL, with severely low AMH below 0.5 ng/mL — indicates diminished ovarian reserve (DOR): fewer remaining follicles than expected for age.

Common Causes of Low AMH

• Natural aging: The most common cause — AMH declines predictably as the follicle pool is depleted with each menstrual cycle
• Diminished ovarian reserve (DOR): Age-inappropriate decline, sometimes detected in women in their 20s or 30s
• Ovarian surgery: Cystectomy (especially for endometriomas) can remove healthy ovarian tissue alongside the cyst
• Chemotherapy or pelvic radiation: Gonadotoxic treatments can accelerate follicle loss
• Endometriosis: Associated with lower AMH, independent of surgical history
• Smoking: Associated with earlier ovarian aging and modestly lower AMH
• Primary ovarian insufficiency (POI): Very low or undetectable AMH before age 40

The clinical impact of low AMH is primarily on egg quantity retrievable during IVF stimulation, not on the ability to conceive naturally. A woman with low AMH who is still ovulating regularly and has open fallopian tubes can conceive spontaneously — low AMH lowers the odds and shortens the practical window, but it is not equivalent to infertility. It does, however, predict a lower egg yield and higher cycle cancellation risk if ovarian stimulation is pursued, which is why low-AMH patients are often counseled toward earlier evaluation and, if desired, earlier fertility treatment.

High AMH Levels — PCOS & Polycystic Ovaries

High AMH — typically above 3.5-4.0 ng/mL, or above the age-specific 95th percentile — usually reflects a higher-than-average number of small antral follicles. Elevated AMH is one of the most consistent hormonal findings in polycystic ovary syndrome (PCOS), where follicles accumulate at a small size but fail to mature and ovulate normally.

• PCOS association: AMH levels in women with PCOS are often 2-3× higher than age-matched controls, and some diagnostic algorithms now use AMH as a supportive criterion alongside irregular cycles and hyperandrogenism
• OHSS risk marker: High AMH going into IVF stimulation predicts a strong response and raises the risk of ovarian hyperstimulation syndrome (OHSS) — clinics typically respond with lower gonadotropin doses and antagonist protocols
• Not a fertility guarantee: High AMH indicates a large follicle pool, but PCOS-related anovulation can still make natural conception difficult without ovulation induction

AMH Test — How It Works & What to Expect

The AMH blood test (anti-Müllerian hormone test) is a simple serum draw with several practical advantages over other ovarian reserve markers:

• No cycle-day requirement: Unlike day-3 FSH, AMH can be drawn on any day of the menstrual cycle
• No fasting required
• Minimal intra-cycle variability: AMH shows far less fluctuation than FSH or estradiol across a single cycle
• Turnaround time: Results are typically available in 1-3 business days, depending on the assay platform
• Assay platforms: ELISA, chemiluminescent immunoassay (CLIA/ECLIA), and fluorescence immunoassay (FIA) are all used to quantify AMH, generally with a working range of approximately 0.01-20+ ng/mL

One important technical caveat for both clinicians and IVD developers: early-generation AMH ELISA kits were affected by complement-related sample interference, which could cause inconsistent results between assay generations and required revised sample handling protocols. Modern automated AMH immunoassays have largely resolved this issue, but it underscores why AMH results should always be compared using the same assay platform over time whenever possible, and why antibody pair specificity and sample pretreatment validation are critical in AMH IVD assay design. IVD developers can read our AMH antibody pair selection guide for the full epitope pairing and cross-reactivity screening process.

AMH Levels & IVF Success Rates

AMH is the strongest single hormonal predictor of ovarian response to stimulation — how many eggs will likely be retrieved in an IVF cycle — and is used routinely to individualize gonadotropin starting doses. Higher AMH generally predicts a higher egg yield; lower AMH predicts a lower yield and a greater chance of cycle cancellation due to poor response.

This distinction — AMH predicts quantity, not quality — is the single most important concept for patients to understand. A 38-year-old with high AMH will likely yield many eggs during stimulation, but her live birth rate per embryo remains governed by age-related aneuploidy risk. Conversely, a 30-year-old with low AMH may yield fewer eggs but often retains age-typical egg quality, meaning cumulative success across multiple stimulation cycles or accumulated embryos can still be favorable. AMH-based individualized dosing has been shown to improve cycle safety and reduce both under- and over-response compared with fixed-dose protocols. (Source: La Marca et al., Hum Reprod Update 2010)

Frequently Asked Questions About AMH